Brain-derived blood extracellular vesicles as potential biomarkers in multiple sclerosis (MS): Pilot results from relapsing MS patients receiving anti-CD20 therapy

被引：0
|
作者：
Anandan, Shamundeeswari [1 ,2 ]
Feliciello, Giancarlo [3 ]
Werner-Klein, Melanie [4 ]
Stojanovic, Natasa [3 ]
Torkildsen, Oivind [1 ,2 ]
Myhr, Kjell-Morten [1 ,2 ]
机构：
[1] Haukeland Hosp, Dept Neurol, NeuroSysMed, Bergen, Norway
[2] Univ Bergen, Dept Clin Med, Bergen, Norway
[3] Fraunhofer Inst Toxicol & Expt Med, Personalized Tumor Therapy, Regensburg, Germany
[4] Univ Regensburg, Expt Med & Therapy Res, Regensburg, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P257/188
引用
收藏
页码：305 / 306
页数：2
相关论文
共 30 条
  • [11] Retrospective data analysis of a German cohort of patients with active relapsing multiple sclerosis switching from anti-CD20 therapies to cladribine tablets and vice versa
    Konen, Franz Felix
    Pfeuffer, Steffen
    Jendretzky, Konstantin Fritz
    Gehring, Klaus
    Elias-Hamp, Birte
    Suehs, Kurt-Wolfram
    Pawlitzki, Marc
    Meuth, Sven
    Kleinschnitz, Christoph
    Pul, Refik
    Skripuletz, Thomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 328 - 330
  • [12] Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
    Rico, Audrey
    Ninove, Laetitia
    Maarouf, Adil
    Boutiere, Clemence
    Durozard, Pierre
    Demortiere, Sarah
    Villarroel, Paola Mariela Saba
    Amroun, Abdennour
    Fourie, Toscane
    de Lamballerie, Xavier
    Pelletier, Jean
    Audoin, Bertrand
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [13] Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis
    Steinman, Lawrence
    Fox, Edward
    Hartung, Hans-Peter
    Cree, Bruce
    Alvarez, Enrique
    Qian, Peiqing
    Wray, Sibyl
    Robertson, Derrick
    Huang, Deren
    Selmaj, Krzystof
    Wynn, Daniel
    Weiss, Michael
    Bosco, Jenna
    Power, Sean
    Mok, Koby
    NEUROLOGY, 2020, 94 (15)
  • [14] OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Piccolo, Rebecca
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1101 - 1102
  • [15] Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
    Bar-Or, Amit
    Thanei, Gian-Andrea
    Harp, Christopher
    Bernasconi, Corrado
    Bonati, Ulrike
    Cross, Anne H.
    Fischer, Saloumeh
    Gaetano, Laura
    Hauser, Stephen L.
    Hendricks, Robert
    Kappos, Ludwig
    Kuhle, Jens
    Leppert, David
    Model, Fabian
    Sauter, Annette
    Koendgen, Harold
    Jia, Xiaoming
    Herman, Ann E.
    EBIOMEDICINE, 2023, 93
  • [16] ENT-MS-12 questionnaire: A novel tool to investigate otolaryngology symptoms in patients with relapsing-remitting multiple sclerosis. Results from a pilot study
    Di Stadio, Arianna
    Ralli, Massimo
    Altieri, Marta
    Brenner, Michael J.
    Dipietro, Laura
    Messineo, Daniela
    Kaski, Diego
    Bernitsas, Evanthia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47
  • [17] Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
    Bar-Or, A.
    Thanei, G. -A.
    Harp, C.
    Bernasconi, C.
    Bonati, U.
    Cross, A. H.
    Fischer, S.
    Gaetano, L.
    Hauser, S. L.
    Hendricks, R.
    Kappos, L.
    Kuhle, J.
    Leppert, D.
    Model, F.
    Sauter, A.
    Koendgen, H.
    Jia, X.
    Herman, A. E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 307 - 308
  • [18] Time to multiple sclerosis reactivation after anti-CD20 treatment discontinuation : a retrospective observational study from 4 large French MS Reference centers in the OFSEP national Database
    Vigier, Hugo
    Labauge, Pierre
    De Seze, Jerome
    Zephir, Helene
    Ouallet, Jean-Christophe
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 363 - 364
  • [19] Interferon-β upregulates brain-derived neurotrophic factor secretion from peripheral blood mononuclear cells of relapsing-remitting multiple sclerosis patients through a CD40-dependent mechanism
    Azoulaya, David
    Mausner, Karin
    Urshansky, Natali
    Karni, Arnon
    MULTIPLE SCLEROSIS, 2008, 14 : S162 - S162
  • [20] Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).
    Fox, E.
    Lovett-Racke, A.
    Gormley, M.
    Liu, Y.
    Wray, S.
    Shubin, R.
    Petracca, M.
    Inglese, M.
    Power, S.
    Bosco, J.
    Mok, K.
    Weiss, M.
    Eubanks, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 87 - 87
123